Universal Coaching Centre -

Enter your keyword

8053+ OFFICERS SERVING THE NATION UNIVERSAL COACHING CENTRE Let's join hands together in bringing Your Name in Elite officers list. JOIN US 25 YEARS OF EXCELLENCE MEET NEW FRIENDS AND STUDY WITH EXPERTS JOIN US Nothing is better than having friends study together. Each student can learn from others through by teamwork building and playing interesting games. Following instruction of experts, you and friends will gain best scores.

ULP Click here! Click here! Classroom Programme NRA-CET Test Series
Click here ! Org code: XSHWV

post

NEW DRUG LICENCE PLAN TO TRACK BULK PHARMA PRODUCTS

Why in the News?

  • Regulatory overhaul: The government plans a separate wholesale licensing regime for bulk drugs, APIs, and KSMs, similar to environmental clearance processes for pharmaceutical industries.
  • Safety concerns: Move follows drug safety lapses, including deaths linked to contaminated cough syrups, highlighting the need for stringent environmental impact assessments in pharma manufacturing.
  • Draft in works: A draft notification is being prepared to dismantle the current common licensing system, reminiscent of updates to environmental clearance notifications.

KEY FEATURES OF THE PROPOSED LICENSING REGIME

  • Separate licences: Distinct licences for bulk drug wholesalers and formulation sellers, mirroring sector-specific environmental clearances.
  • Central registry: Creation of a database of nearly 1.2 million bulk drug traders under DCGI oversight, similar to environmental compliance databases.
  • Improved traceability: Enables tracking of imported raw materials, over 70% sourced from China, akin to supply chain assessments in environmental impact studies.
  • Faster accountability: Helps identify dealers supplying substandard or contaminated inputs, supporting the precautionary principle in environmental protection.
  • Stricter standards: Allows enforcement of storage and handling norms for chemical-based inputs, aligning with environmental safety regulations.

SIGNIFICANCE FOR INDIA’S PHARMA SECTOR

  • Reputation repair: Aims to restore India’s image as the “Pharmacy of the World”, while also addressing environmental concerns in pharmaceutical production.
  • Supply-chain intelligence: Addresses gaps in API trade data and value-chain mapping, supporting comprehensive environmental impact assessments.
  • Domestic manufacturing: Complements PLI schemes and minimum import price (MIP) measures, potentially influencing environmental clearance processes for new manufacturing units.
  • Ease of business: Provides a legal framework for compliant bulk drug wholesalers, potentially streamlining environmental clearance procedures.
  • Market scale: Strengthens regulation in a $50-billion pharma market with a fast-growing API segment, necessitating robust environmental jurisprudence.

ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)
● Definition: APIs are the active components responsible for a drug’s therapeutic effect, often subject to environmental impact assessments.
● Strategic importance: Critical for drug quality, safety, and efficacy, with environmental implications throughout their lifecycle.
● Import dependence: India relies heavily on API imports, especially from China, raising concerns about environmental standards in sourcing countries.
● Policy focus: Government promotes API manufacturing via PLI schemes, potentially requiring new environmental clearance processes.
● Public health link: Weak API regulation can lead to serious safety and mortality risks, underscoring the need for stringent environmental and health impact assessments.